Holen Sie sich die Stockscreener-App
11.95
4.64%
0.53
Handel nachbörslich:
11.95
Schlusskurs vom Vortag:
$11.42
Offen:
$11.4
24-Stunden-Volumen:
24,494
Relative Volume:
0.16
Marktkapitalisierung:
$650.12M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-1.73%
1M Leistung:
+22.69%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$11.40
$11.99
1-Wochen-Bereich:
$11.11
$12.03
52-Wochen-Spanne:
$9.54
$13.50
Alumis Inc Stock (ALMS) Company Profile
Firmenname
Alumis Inc
Sektor
Branche
Telefon
650-231-6625
Adresse
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Alumis Inc Aktie (ALMS) Neueste Nachrichten
New Survey Data Highlights the Importance of Prioritizing Mental Health for Canadians Living with IBD - Quantisnow
Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference - StockTitan
Alumis (NASDAQ:ALMS) Rating Increased to Strong-Buy at Baird R W - MarketBeat
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Robert W. Baird Begins Coverage on Alumis (NASDAQ:ALMS) - MarketBeat
Baird Initiates Coverage of Alumis (ALMS) with Outperform Recommendation - MSN
Baird starts Alumis coverage with Outperform, $25 target - Investing.com India
Baird starts Alumis coverage with Outperform, $25 target By Investing.com - Investing.com South Africa
When (ALMS) Moves Investors should Listen - Stock Traders Daily
This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - MSN
Alumis (NASDAQ:ALMS) Stock Price Down 4.5%Time to Sell? - MarketBeat
Alumis (NASDAQ:ALMS) Trading 3.1% HigherWhat's Next? - MarketBeat
HC Wainwright Estimates Alumis' Q3 Earnings (NASDAQ:ALMS) - MarketBeat
Analysts Set Curbline Properties (NYSE:CURB) PT at $24.19 - Defense World
Ambev (NYSE:ABEV) Now Covered by StockNews.com - Defense World
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside - AOL
Alumis (NASDAQ:ALMS) Shares Gap UpHere's Why - MarketBeat
H.C. Wainwright sets Buy rating on Alumis stock - Investing.com
H.C. Wainwright sets Buy rating on Alumis stock, cites TYK2 inhibitor - Investing.com Australia
H.C. Wainwright sets Buy rating on Alumis stock By Investing.com - Investing.com UK
Alumis Inc. (NASDAQ:ALMS) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
(ALMS) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Shifts in the Psoriasis Market Suggest Strong Potential for Emerging Oral Therapies - GlobeNewswire Inc.
Alumis (NASDAQ:ALMS) Stock Price Down 2.6%What's Next? - MarketBeat
Alumis (NASDAQ:ALMS) Shares Up 6.9%What's Next? - MarketBeat
Millennium Management LLC Takes Position in Alumis Inc. (NASDAQ:ALMS) - MarketBeat
Jim Cramer Says He's Buying 'Some Target,' But Dismisses SoundHound AI As 'Meme Stock' - Benzinga
Cramer's Lightning Round: 'I like Target right here' - CNBC
Uveitis Market Growth to Accelerate in Forecast Period - openPR
Alumis (NASDAQ:ALMS) Trading Up 3.8%Time to Buy? - MarketBeat
(ALMS) Technical Pivots with Risk Controls - Stock Traders Daily
Alumis: Could This Broken Immunology IPO Become The Next Amgen? (ALMS) - Seeking Alpha
Strategy Shares NASDAQ 7 HANDL ETF (NASDAQ:HNDL) is Kades & Cheifetz LLC’s 3rd Largest Position - Defense World
Promising Long-term Results for ESK-001 in Psoriasis - Dermatology Times
Alumis (NASDAQ:ALMS) Stock Price Down 4.8% - MarketBeat
Alumis reports progress in psoriasis treatment trial By Investing.com - Investing.com South Africa
Alumis reports progress in psoriasis treatment trial - Investing.com India
Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study - ForexTV.com
ALMSAlumis Inc. Latest Stock News & Market Updates - StockTitan
Creating Equitable AI Models for Multiple Myeloma - AJMC.com Managed Markets Network
Alumis (NASDAQ:ALMS) Trading Up 4.8% - MarketBeat
(ALMS) Technical Data - Stock Traders Daily
Alumis (NASDAQ:ALMS) Shares Gap Down to $11.86 - Defense World
Yu Fan Purchases New Stake in Alumis Inc. (NASDAQ:ALMS) - MarketBeat
Alumis Inc. [ALMS] Stock bought by Insider Foresite Labs, LLC for $40.0 million - Knox Daily
Taking on analysts’ expectations and winning: Alumis Inc. (ALMS) - SETE News
SR One Capital Management LP Invests $26.07 Million in Alumis Inc. (NASDAQ:ALMS) - MarketBeat
Alumis (NASDAQ:ALMS) Shares Down 2.6% - MarketBeat
Alumis (NASDAQ:ALMS) Trading 5.3% Higher - MarketBeat
Alumis (NASDAQ:ALMS) Stock Price Up 5.3% - Defense World
Alumis (NASDAQ:ALMS) Reaches New 12-Month Low at $10.37 - MarketBeat
Finanzdaten der Alumis Inc-Aktie (ALMS)
Es liegen keine Finanzdaten für Alumis Inc (ALMS) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):